- Home
- EQIX vs BMY Comparison
EQIX vs BMY Comparison
Compare EQIX & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EQIX | BMY |
|---|---|---|
| Founded | 1998 | 1887 |
| Country | United States | United States |
| Employees | N/A | 32500 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.6B | 113.5B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | EQIX | BMY |
|---|---|---|
| Price | $1,084.32 | $62.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 24 | 15 |
| Target Price | ★ $1,076.87 | $61.73 |
| AVG Volume (30 Days) | 527.8K | ★ 9.9M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | 1.90% | ★ 4.38% |
| EPS Growth | ★ 61.88 | N/A |
| EPS | ★ 4.20 | N/A |
| Revenue | ★ $5,998,545,000.00 | N/A |
| Revenue This Year | $12.35 | N/A |
| Revenue Next Year | $8.88 | N/A |
| P/E Ratio | $258.15 | ★ $17.26 |
| Revenue Growth | ★ 7.85 | N/A |
| 52 Week Low | $720.62 | $42.52 |
| 52 Week High | $1,128.68 | $62.89 |
Technical Indicators
Market Signals| Indicator | EQIX | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 60.47 | 65.86 |
| Support Level | $1,042.67 | $56.46 |
| Resistance Level | $1,097.77 | N/A |
| Average True Range (ATR) | 22.70 | 1.42 |
| MACD | 7.17 | 0.40 |
| Stochastic Oscillator | 78.42 | 97.68 |
Price Performance
Historical ComparisonAbout EQIX Equinix Inc. REIT
Equinix is one of the leading providers of cloud- and carrier-neutral data centers, offering colocation and interconnection services to hyperscalers and businesses. Equinix operates 270 properties in 77 metropolitan areas across 36 countries, serving over 10,000 customers. About 70% of Equinix's revenue comes from renting physical space, which allows hyperscalers and other clients to store servers, data storage, and networking equipment. The other 30% of revenue is generated primarily through interconnection services (20%) and other managed services (10%).
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.